When used as monotherapy, tirzepatide has a low risk of hypoglycemia
Those with diabetes or significant insulin resistance may benefit from tirzepatide stronger glucose-lowering effects
Morbid obesity in PWS leads to increased risk of cardiopulmonary compromise, type 2 diabetes mellitus (DM), chronic leg edema, premature cardiovascular disease, and death [1,2]
Peptides for weight loss are, in research terms, a class of receptor agonists that produce a dose-dependent reduction in body weight in animal models and clinical trials
These results show in a second biological system tested that in vivo NERNST responses are usually dominated by the catalysed interaction of its roGFP2 domain with the glutathione redox couple
So, confounding factors remain (for example: underlying diabetes, obesity, other vascular risk, rapid weight loss, pre-existing eye disease)